ALPHA COGNITION INC (ACOG) Stock Price & Overview
NASDAQ:ACOG • CA02074J5017
Current stock price
The current stock price of ACOG is 6.75 USD. Today ACOG is up by 4.01%. In the past month the price increased by 17.19%. In the past year, price increased by 63.83%.
ACOG Key Statistics
- Market Cap
- 146.948M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.17
- Dividend Yield
- N/A
ACOG Stock Performance
ACOG Stock Chart
ACOG Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ACOG. When comparing the yearly performance of all stocks, ACOG is one of the better performing stocks in the market, outperforming 86.82% of all stocks.
ACOG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACOG. ACOG has a great financial health rating, but its profitability evaluates not so good.
ACOG Earnings
On March 26, 2026 ACOG reported an EPS of -0.31 and a revenue of 2.79M. The company missed EPS expectations (-12.56% surprise) and missed revenue expectations (-14.38% surprise).
ACOG Forecast & Estimates
7 analysts have analysed ACOG and the average price target is 18.36 USD. This implies a price increase of 172% is expected in the next year compared to the current price of 6.75.
For the next year, analysts expect an EPS growth of -18.13% and a revenue growth 128.58% for ACOG
ACOG Groups
Sector & Classification
ACOG Financial Highlights
Over the last trailing twelve months ACOG reported a non-GAAP Earnings per Share(EPS) of -1.17.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.06% | ||
| ROE | -57.42% | ||
| Debt/Equity | 0 |
ACOG Ownership
ACOG Latest News, Press Relases and Analysis
ACOG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 371.899B | ||
| AMGN | AMGEN INC | 15.25 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.68 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.84 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.2 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.55 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACOG
Company Profile
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Company Info
IPO: 2021-06-09
ALPHA COGNITION INC
c/o 1200 - 750 West Pender Street
Vancouver BRITISH COLUMBIA CA
Employees: 52
Phone: 16045649244
ALPHA COGNITION INC / ACOG FAQ
Can you describe the business of ALPHA COGNITION INC?
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
What is the stock price of ALPHA COGNITION INC today?
The current stock price of ACOG is 6.75 USD. The price increased by 4.01% in the last trading session.
Does ACOG stock pay dividends?
ACOG does not pay a dividend.
How is the ChartMill rating for ALPHA COGNITION INC?
ACOG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ACOG stock listed?
ACOG stock is listed on the Nasdaq exchange.
Can you provide the market cap for ALPHA COGNITION INC?
ALPHA COGNITION INC (ACOG) has a market capitalization of 146.95M USD. This makes ACOG a Micro Cap stock.